ON-DEMAND PRESENTATIONSkeyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
ON-DEMAND PRESENTATIONS
keyboard_arrow_leftSearch & Filter
search
Topics
ON-DEMAND PRESENTATIONS
search
Topics
On Demand
Antibody Selection and Screening and Antibody Affinity Maturation
Minimizing Deviation from Fully Human Germline Antibody Sequences During Affinity Maturation
On Demand
Therapeutic Targets for Antibodies
Dual Specificity PD-L1/PD-L2 Antibodies Treat Both Immune “Hot” and “Cold” Cancers
On Demand
Bispecifics, ADCs, Immune-Oncology and CAR T-cells
REGN4018 is a Mucin 16 Bispecific T cell–engaging Antibody for the Treatment of Ovarian Cancer
On Demand
Improving Antibody Properties
Systems Engineering to Design More Effective Monoclonal Therapeutics
On Demand
Antibody Structure Insights
The Structural Role of N-Glycosylation in interactions between Antibodies and Receptors
On Demand
New Developments in Antibody R&D
Human Monoclonal Antibodies for SARS-CoV-2
On Demand
Antibody Selection and Screening and Antibody Affinity Maturation
Affinity Maturation of Therapeutic Antibodies Using Mammalian Cell Display Coupled with in vitro Somatic Hypermutation Mimics Natural Maturation
On Demand
Improving Antibody Properties
Engineered Fc-glycosylation Switch to Eliminate Antibody Effector Function
On Demand
Improving Antibody Properties
The Precise Humanization of Immunoglobulin Constants and High and Low Affinity hFcγRs to Replicate Human Antibody Effector Function in Mice
On Demand
Antibody Selection and Screening and Antibody Affinity Maturation
Biophysical Properties of Human B cell-derived Antibodies
- Laura Walker, Ph.D - Associate Director, Adimab, LLC.
On Demand
Antibody Selection and Screening and Antibody Affinity Maturation
Using E.coli to Identify Aggregation Propensity in Therapeutic and Disease-causing Proteins
- David Brockwell, PhD - Associate Professor, University of Leeds
On Demand
Therapeutic Targets for Antibodies
Effective Engagement of TNFR-SF Members by Antibody Approaches
On Demand
Bispecifics, ADCs, Immune-Oncology and CAR T-cells
Bispecific Antibody T cell-engagers
On Demand
Improving Antibody Properties
Probody Therapeutics in the Treatment of Cancer
ON-DEMAND PRESENTATIONS 10:15am - 11:15am60 mins
Antibody Selection and Screening and Antibody Affinity Maturation
Using Multiplexed Flow Cytometry to ScreenAntibodies and Sera
On Demand
Therapeutic Targets for Antibodies
Inhibition of TGFβ1 Activation with SRK-181 Overcomes Primary Resistance to Checkpoint Inhibition Therapy
On Demand
Bispecifics, ADCs, Immune-Oncology and CAR T-cells
Engineering Bispecific Antibodies as Therapeutics: Utilizing Intrinsic Heavy/Light Chain Pairing Preferences and Mitigating High Viscosity
- Paul Carter, PhD - Senior Director and Staff Scientist , Antibody Engineering, Genentech, Inc.
On Demand
Antibody Selection and Screening and Antibody Affinity Maturation
Massively Multiplexed and Quantitative Characterization of Antibody-antigen Interactions
On Demand
Therapeutic Targets for Antibodies
Human-derived Antiviral Antibodies - Accelerating Antibody Discovery Timelines
On Demand
Bispecifics, ADCs, Immune-Oncology and CAR T-cells
Engineered Avibodies (enhanced Diabodies) Precisely Loaded with Novel ADC Payloads that Surpass IgG-ADCs in Cancer Therapy
On Demand
Therapeutic Targets for Antibodies
A Novel Therapeutic Antibody Targeting Human Osteoprotegerin Attenuates Severe Experimental Pulmonary Arterial Hypertension
On Demand
Bispecifics, ADCs, Immune-Oncology and CAR T-cells
A Coiled-Coil Masking Domain for Selective Activation of Therapeutic Antibodies
On Demand
Therapeutic Targets for Antibodies
NGM621: A Potent Inhibitory anti-Complement C3 Antibody for Treatment of Geographic Atrophy
On Demand
Bispecifics, ADCs, Immune-Oncology and CAR T-cells
Antibody Fragment Drug Conjugates (FDCs) a Tailored Solution for Solid Tumours
On Demand
Therapeutic Targets for Antibodies
Two Tales of Targeting MerTK
On Demand
Bispecifics, ADCs, Immune-Oncology and CAR T-cells
Cellular Screening Platforms for Engineering T cell Receptors and Chimeric Antigen Receptors
- Sai Reddy, PhD - Assistant Professor, Department of Biosystems Science & Engineering, ETH Zurich
On Demand
Therapeutic Targets for Antibodies
Innovative Therapeutics for Severe COVID-19 and ARDS by Combining ACE2-Fc with a Potent Complement Inhibitor
On Demand
Bispecifics, ADCs, Immune-Oncology and CAR T-cells
TCR Engineering
On Demand
Bispecifics, ADCs, Immune-Oncology and CAR T-cells
Parallel Engineering of Immune Cell Genomes by Pooled Knockin Targeting
On Demand
Bispecifics, ADCs, Immune-Oncology and CAR T-cells
Designer Cytokines for Targeted Immune Modulation
On Demand
Bispecifics, ADCs, Immune-Oncology and CAR T-cells
Therapeutic Targeting of a Novel NK- and T-cell Immune Checkpoint
On Demand
Bispecifics, ADCs, Immune-Oncology and CAR T-cells
Anti-GITR Antibody Development
Filter
Topics